Centene vs Genmab
Centene (CNC), health care, and Genmab (GMAB), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Centene is worth $35.9B on the stock market and Genmab $32B: Centene is valued at 12% more. Centene trades at 24.9 times earnings and Genmab at 44.4; operating margins in their latest fiscal years were -3.91% and 28.6%. Over the past year Centene's share price has moved +102% and Genmab's +70.1%.
Key facts
- Centene market value
- $35.9B
- Genmab market value
- $32B
- Centene P/E
- 24.9
- Genmab P/E
- 44.4
- Centene revenue
- $194.8BFY to 2025-12-31
- Genmab revenue
- $3.7BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Centene | Genmab |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $35.9Bhigher | $32Blower |
| Revenue | $194.8Bhigher | $3.7Blower |
| Earnings | -$6.7Blower | $963Mhigher |
| Employees | 61,100higher | 3,244lower |
| Total assets | $76.7Bhigher | $12.9Blower |
| Valuation | ||
| P/E | 24.9lower | 44.4higher |
| P/S | 0.2lower | 8.6higher |
| P/B | 1.6 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | -3.91%lower | 28.6%higher |
| Balance sheet | ||
| Net assets | $20Bhigher | $5.8Blower |
| Total liabilities | $56.7Bhigher | $7Blower |
| Total debt | $17.5Bhigher | $5.3Blower |
| Cash on hand | $17.9Bhigher | $1.7Blower |
| Price change | ||
| Today | -2.97%lower | +0.76%higher |
| 1 year | +102%higher | +70.1%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Percentages are each holding's share of that investor's reported portfolio. Who owns CNC · Who owns GMAB
More on Centene
Further comparisons
Centene against its closest peers
Genmab against its closest peers
Learn
Questions and answers
Which is bigger, Centene or Genmab?
By market value, Centene is the larger: $35.9B against $32B for Genmab. By revenue in its latest fiscal year, Centene is the larger: $194.8B against $3.7B for Genmab.
Which has the higher P/E ratio?
Genmab: 44.4, against 24.9 for Centene. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Genmab: 28.6%, against -3.91% for Centene. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Centene: $17.5B, against $5.3B for Genmab. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Centene and Genmab?
None of the tracked superinvestors holds both in their latest 13F filing. 11 hold Centene and 1 holds Genmab.
Cite this page
Funkfolio, “Centene vs Genmab”, data as of 17 November 2026. https://funkfolio.com/compare/cnc-vs-gmab
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.